Ling Xu, Li Wei, Renzhong Zhang, Jinyu Li, Fei Xie
Pterygium, characterized by conjunctival overgrowth onto the cornea, poses recurrence risks post-surgery. This study evaluated the efficacy of pranoprofen + tobramycin/dexamethasone vs. tobramycin/dexamethasone alone in 108 patients (55 observation, 53 control) randomized post-pterygium surgery (March 2023–March 2024). Outcomes included ocular pain (VAS), tear inflammatory factors (IgE, IL-6, IL-8, TNF-?), tear stability (BUT, CESS, SIt), quality of life (OSDI), adverse events and recurrence at 1 day, 1 week and 4 weeks postoperatively. At 1 week, the observation group reported superior pain relief (P0.05), though the observation group trended lower. In conclusion, Pranoprofen + tobramycin/dexamethasone offers enhanced pain control, tear function and anti-inflammatory effects, with a potential recurrence-lowering benefit, supporting its clinical utility in pterygium management.
Pterygium
pranoprofen
tobramycin and dexamethasone
tears
inflammatory factors.